周期素依赖性激酶10与肿瘤发生

国际肿瘤学杂志››2014,Vol. 41››Issue (11): 811-812.doi:10.3760/cma.j.issn.1673-422X.2014.11.004

周期素依赖性激酶10与肿瘤发生

漯河医学高等专科学校药学系

出版日期:2014-12-03发布日期:2015-01-20
通讯作者:游颜杰，Email: youyanjie@163.com
基金资助:

河南省科技攻关计划（142102310464）

Cyclin-dependent kinase 10 and tumorigenesis

Department of Pharmacy, Luohe Medical College, Luohe 462002, China

Online:2014-12-03Published:2015-01-20
Contact:You Yanjie, Email: youyanjie@163.com

摘要/Abstract

摘要：周期素依赖性激酶10（CDK10）通过与转录因子Ets2相互作用参与调控细胞周期，发挥抑癌基因的作用。研究表明CDK10表达下调与多种肿瘤形成密切相关，提示CDK10有希望成为针对恶性肿瘤的潜在分子诊断标志物和治疗靶点。

游颜杰, 李文梅, 刘佳佳, 苑艺. 周期素依赖性激酶10与肿瘤发生[J]. 国际肿瘤学杂志, 2014, 41(11): 811-812.

YOU Yan-Jie, LI Wen-Mei, LIU Jia-Jia, YUAN Yi. Cyclin-dependent kinase 10 and tumorigenesis[J]. Journal of International Oncology, 2014, 41(11): 811-812.

［1］ Yasutis KM, Kozminski KG. Cell cycle checkpoint regulators reach a zillion［J］. Cell Cycle, 2013, 12(10):15011509. ［2］ Yeh CW, Kao SH, Cheng YC. Knockdown of cyclindependent kinase 10 (cdk10) impairs neural progenitor survival via modulation of raf1a expression［J］. J Biol Chem, 2013, 288(39):2792727939. ［3］ Marquardt JU, Seo D, GómezQuiroz LE, et al. Loss of cMet accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways［J］. Biochim Biophys Acta, 2012, 1822(6):942951. ［4］ Yu JH, Zhong XY, Zhang WG, et al. CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells［J］. Oncol Rep， 2012， 27(4):12661276. ［5］ Zhong XY, Xu XX, Yu JH, et al. Clinical and biological significance of Cdk10 in hepatocellular carcinoma［J］. Gene, 2012, 498(1):6874. ［6］ You Y, Yang W, Wang Z, et al. Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas［J］. Cell Oncol (Dordr), 2013, 36(4):323331. ［7］ Leman ES, Magheli A, Yong KM, et al. Identification of nuclear structural protein alterations associated with seminomas［J］. J Cell Biochem， 2009， 108(6):12741279. ［8］ You Y, Chen Y, Zheng X, et al. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients［J］. Cancer Lett, 2012, 315(2):138144. ［9］ Toyota M, Suzuki H, Yamashita T, et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy［J］. Cancer Sci, 2009, 100(5):787791. ［10］ Ran Y, Wu S, You Y. Demethylation of Ecadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy［J］. J Biochem, 2011, 149(1):4954. ［11］ Heller G, Ziegler B, Brandstetter A, et al. CDK10 is not a target for aberrant DNA methylation in breast cancer［J］. Anticancer Res, 2009, 29(10):39393944. ［12］ Guen VJ, Gamble C, Flajolet M, et al. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome［J］. Proc Natl Acad Sci USA, 2013, 110(48):1952519530. ［13］ Liu Y, Xiao Z, Yang D, et al. Effects of the cyclindependent kinase 10 (CDK10) on the tamoxifen sensitivity of keloid samples［J］. Molecules, 2012, 17(2):13071318. ［14］ Zheng T, Nibau C, Phillips DW, et al. CDKG1 protein kinase is essential for synapsis and male meiosis at high ambient temperature in Arabidopsis thaliana［J］. Proc Natl Acad Sci USA, 2014,111(6):21822187. ［15］ Khanal P, Yun HJ, Lim SC, et al. Proyl isomerase Pin1 facilitates ubiquitinmediated degradation of cyclindependent kinase 10 to induce tamoxifen resistance in breast cancer cells［J］. Oncogene, 2012, 31(34):38453856. ［16］ Liu W， Cai MJ， Wang JX， et al. In a nongenomic action, steroid hormone 20hydroxyecdysone induces phosphorylation of cyclindependent kinase 10 to promote gene transcription［J］. Endocrinology, 2014, 155(5):17385170.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.